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Research in two fronts has enabled the development of therapies that provide significant benefit to
cancer patients. One area stems from a detailed knowledge of mutations that activate or inactivate
signaling pathways that drive cancer development. This work triggered the development of tar-
geted therapies that lead to clinical responses in the majority of patients bearing the targeted
mutation, although responses are often of limited duration. In the second front are the advances
in molecular immunology that unveiled the complexity of the mechanisms regulating cellular im-
mune responses. These developments led to the successful targeting of immune checkpoints to
unleash anti-tumor T cell responses, resulting in durable long-lasting responses but only in a frac-
tion of patients. In this Review, we discuss the evolution of research in these two areas and propose
that intercrossing them and increasing funding to guide research of combination of agents repre-
sent a path forward for the development of curative therapies for the majority of cancer patients.Introduction
The scientific community united against a common enemy in
1971 when President Nixon signed a bill initiating the ‘‘War on
Cancer,’’ which provided funding for scientific research focused
on improving our understanding and treatment of cancer.
Without doubt, the intervening years were followed by great
advances in the elucidation of the molecular mechanisms that
regulate growth and death of normal cells, including a deep
understanding of how these pathways progressively go awry
during the development of cancer. This understanding led to
the era of genomically targeted therapies and ‘‘precision medi-
cine’’ in the treatment of cancer. Genomically targeted therapies
can result in remarkable clinical responses. The ability of cancer
cells to adapt to these agents by virtue of their genomic insta-
bility and other resistance mechanisms eventually leads to
disease progression in the majority of patients nonetheless.
Unraveling themechanisms bywhich cancer cells become resis-
tant to drugs and developing new agents to target the relevant
pathways have become logical next steps in this approach for
cancer treatment. However, given the genetic and epigenetic
instability of cancer cells, it is likely that each new drug or com-
bination of drugs targeting the tumor cells will meet with more
complex mechanisms of acquired resistance. Recent findings
suggest that T cells, bearing antigen receptors that are gener-
ated by random rearrangement of gene segments, followed by
selective processes that result in a vast repertoire of T cell
clones, provide sufficient diversity and adaptability to match
the complexity of tumors. Discoveries regarding regulation of
T cell responses have provided key principles regarding immunecheckpoints that are being translated into clinical success, with
durable responses and long-term survival greater than 10 years
in a subset of patients with metastatic melanoma, as well as
yielding promising results in several other tumor types. Now,
with the perspective of combining genomically targeted agents
and immune checkpoint therapies, we are finally poised to
deliver curative therapies to cancer patients. To support this
goal and accelerate these efforts, changes in directions of
research support and funding may be required.
Precision Medicine: Targeting the Drivers
In the past three decades, enormous strides have been made in
elucidating the molecular mechanisms involved in the develop-
ment of cancer (Hanahan and Weinberg, 2011). It is now clear
that the oncogenic process involves somatic mutations that
result in activation of genes that are normally involved in regula-
tion of cell division and programmed cell death, as well as inac-
tivation of genes involved in protection against DNA damage or
driving apoptosis (Bishop, 1991; Solomon et al., 1991;Weinberg,
1991; Knudson, 2001). These genetic links led to the decision
early in the war on cancer to undertake sequencing of cancer
genomes to provide a comprehensive view of somatic muta-
tional landscapes in cancer and identify possible therapeutic tar-
gets. Infrastructure and funding were provided to coordinate the
sequencing efforts. It has become apparent that the level of
somatic mutations differs widely between and within different
tumor types ranging from very low rates in childhood leukemias
to very high rates in tumors associated with carcinogens (Alex-
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Mutations can be divided into two broad classes: those whose
products ‘‘drive’’ tumorigenesis in a dominant fashion and ‘‘pas-
sengers’’ with no obvious role in the tumor causation. The Can-
cer Genome Atlas (TCGA) projects have enabled identification of
many of these mutations (Chen et al., 2014; Cancer Genome
Atlas Research Network, 2014). This has allowed for the rational
design of drugs that target and selectively interfere with onco-
genic signaling pathways. This approach has revolutionized
cancer medicine by moving away from the ‘‘one size fits
all’’ approach—for instance, traditional chemotherapy, which
attacks all dividing cells, including both cancer-differentiating
or regenerating normal cells—to a more personalized strategy
of treating patients with a specific drug only if their cancer bears
particular molecular mutations that are target of that drug.
As an example of genomically targeted therapies, an inhibitor
against BRAF was developed when it was discovered that
40%–60% of cutaneous melanomas carry mutations in
BRAF, which induces constitutive activation of the MAPK
pathway (Curtin et al., 2005; Davies et al., 2002). In a randomized
phase III trial comparing a BRAF inhibitor (vemurafenib) versus
dacarbazine, the vemurafenib treatment group had a response
rate of 48% versus 5% in the dacarbazine arm (Chapman
et al., 2011). However, the median duration of response was
short, only 6.7 months (Sosman et al., 2012). Another oncogenic
pathway that has been targeted is the tyrosine kinase chromo-
somal rearrangement, which results in the fusion oncogene
EML4-ALK that is found in 5% of NSCLC patients (Soda
et al., 2007). The EML4 fusion partner mediates ligand-indepen-
dent oligomerization and/or dimerization of anaplastic lym-
phoma kinase (ALK), resulting in constitutive kinase activity.
Standard chemotherapies in this subgroup of patients have
been associated with response rates of up to 10% (Hanna
et al., 2004). Crizotinib, a tyrosine kinase inhibitor targeting
ALK (Kwak et al., 2010), was shown to elicit a response rate of
65%with a median duration of response of less than 8 months
in a phase III trial (Shaw et al., 2013). Although there was a signif-
icant increase in progression-free survival for patients treated
with crizotinib, regrettably, there was no overall survival benefit
in the interim analysis. Therefore, although the concept of target-
ing ‘‘driver mutations’’ has great merit and has demonstrated
clinical responses, the reality remains that the majority of
patients treated with these agents will derive short-term clinical
responses with eventual development of resistance mecha-
nisms that lead to disease progression and death.
Mechanisms operative in acquired resistance fall into three
main categories: alterations in the targeted gene (as a result of
mutation, amplification, or alternative splicing); other changes
that do not affect the original target but re-activate the signaling
pathway involved (i.e., NRAS and MEK mutations in BRAF
mutant melanoma); and changes that activate alternate path-
ways (such as activation of growth factor receptors). Consider-
able effort has gone into finding ways to enhance efficacy of
genomically targeted therapies. One effort involves multiple
agents that target different molecules in the same pathway,
such as the combination of a BRAF inhibitor and a MEK-inhibitor
(Larkin et al., 2014; Robert et al., 2015a). This approach helps to
reduce compensatory feedback loops, as well as to block the
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ways to prevent emerging resistance (Martz et al., 2014). Still,
the chief challenge of these combinatorial approaches is the
multiplicity of resistance mechanisms and the fact that different
mechanisms may be in operation in different cells due to intratu-
mor heterogeneity. Given these observations, it is difficult to
envision realistic approaches to effectively overcome the myriad
of resistance mechanisms that may arise in the course of cancer
treatment. The continued evolvability of the tumor cells and their
mechanisms of escape from targeted therapies raise the ques-
tion as to whether combinations of genomically targeted agents
will ever be curative.
Advantages of Mobilizing T Cells for Cancer Therapy
As the knowledge of the intricate biology of cancer has pro-
gressed, so has the understanding of the fundamental cellular
and molecular mechanisms that orchestrate the interplay of
the innate and adaptive arms of the immune system. In a
simplistic way, the innate system is composed primarily of cyto-
kines, the complement system, and phagocytes such as macro-
phages, neutrophils, dendritic cells, and natural killer (NK) cells.
Cells of the innate immune system have hard-wired receptors to
detect products of infectious microorganisms and dying cells.
Macrophages and neutrophils provide an early defense against
microorganisms, whereas dendritic cells provide a key interface
to the adaptive immune system, composed of B and T cells with
their somatically generated, clonally expressed repertoire of
antigen receptors.
The understanding of the basic principles governing the con-
trolling immunity provided the rational for the development of
powerful strategies to actively engage the immune system for
cancer therapy. Strategies to unleash T cells against tumors
are particularly compelling, as the activity of these cells presents
important features that are advantageous over other cancer
therapies. The first is their specificity. T cells express antigen re-
ceptors that recognize cell-surface complexes of MHC mole-
cules and peptides sampled from virtually all the proteins in the
cell and are not limited to peptide antigens derived from cell-
surface molecules. The second feature is memory. Primary
T cell responses are generally followed by the production of
long-livedmemory T cells with accelerated kinetics of secondary
response if the antigen recurs. Finally, the T cell response is
adaptable and can accommodate not only tumor heterogeneity
but also responses to novel antigens expressed by recurring
tumors. It has been calculated that the somatic recombination
process that generates the antigen receptors of T cells can
generate as many as 1015 different receptors (Davis and Bjork-
man, 1988). Of this theoretical number, each individual human
has perhaps 109 different receptors. The immense size of the
repertoire suggests that the immune system is indeed well
equipped to deal with mutability and adaptability of cancer.
Harnessing T Cell Responses to Tumor Antigens
With the advent of genomic and cDNA expression cloning
methods and sequencing of peptides eluted from tumor cell
MHC molecules, an avalanche of tumor antigens defined by
tumor-specific T cells has been identified in both mice and in hu-
mans. Most of these are shared between cancer cells of different
individuals and fall into four groups: products of oncogenic
viruses (Epstein-Barr virus in certain leukemias and human
papilloma virus in cervical and some head and neck cancers);
antigens related to tissue-specific differentiation molecules
(tyrosinase and related proteins in melanoma and prostate-spe-
cific antigen and prostatic acid phosphatase in prostate cancer);
molecules normally expressed only during fetal development
(carcino-embryonic antigen in colon cancer, a-fetoprotein in liver
cancer); and cancer-testes (CT) antigens, which are normally ex-
pressed during gametogenesis but are found in many cancer
cells as a result of changes in epigenetic regulation (MAGE and
NY-ESO-1).
Additionally, somatic mutations also can result in the genera-
tion of tumor-specific peptides with the potential to bind major
histocompatibility complex (MHC) molecules and therefore be
recognized by the immune system as neoantigens (Sjo¨blom
et al., 2006; Segal et al., 2008). The analysis of the epitope land-
scape of breast and colon carcinoma cells revealed that the
products of seven to ten mutant genes in colorectal and
breast cancer, respectively, have the potential for binding to
HLA-A*0201 alone. Because each heterozygote individual
carries as many as 6 different HLA class I genes, this means
an average of 42–60 potential neoantigens that can be presented
to T cells. In support of these estimates, recent studies have
demonstrated that neoantigens generated by somatic mutation
are recognized by T cells in bothmouse and human cancers (Lin-
nemann et al., 2015; Gros et al., 2014; Tran et al., 2014; Gubin
et al., 2014).
At first, as a result of earlier studies identifying shared anti-
gens, the field of cancer immunotherapy became focused on
developing therapeutic vaccines to expand T cells against these
shared antigens expressed on tumors. Many studies focused on
stimulating T cell responses with peptides, proteins, whole-
tumor cells including those modified to express cytokines,
DNA, recombinant viral-based vaccines, or antigen-pulsed den-
dritic cells given alone or in combination with various adjuvants
or cytokines. Although these trials were conducted with the
best available science at the time and provided promising anec-
dotal evidence that induction of immune responses could elicit
clinical benefit, they remained largely negative and generally
failed to show objective clinical responses (see Rosenberg
et al., 2004 for review). Enthusiasm waned somewhat as the
number of failed clinical trials mounted.
Many reasons might have contributed to the failure of these
vaccination strategies, including choice of antigen, failure to pro-
vide adequate costimulation, or functional inactivation of tumor-
reactive T cells (Melero et al., 2014). A number of T-cell-extrinsic
suppressive mechanisms such as TGFb, FoxP3+ regulatory
T cells (Treg), and tryptophan metabolites (IDO) that can hamper
anti-tumor responses have also been identified, and there have
been efforts to minimize the suppressive effects of these in
pre-clinical and clinical studies.
Unraveling the Complexity of T Cell Activation
Another contributing factor to the failure of earlier cancer vaccine
trials was perhaps the lack of understanding and appreciation of
the full complexity of cell-intrinsic pathways that regulate T cell
activation. By the late 1980s, it was known that simple engage-ment of peptide/MHC complexes by the antigen receptor is
insufficient for activation of T cells and may render them anergic
(Jenkins and Schwartz, 1987; Mueller et al., 1989). In order to
become fully activated, T cells must encounter antigen in the
context of antigen-presenting cells (APCs) such as dendritic
cells, which provide costimulatory signals mediated by B7 mol-
ecules (B7-1 and B7-2) that will engage their ligand, CD28, in
the T cell (Greenwald et al., 2005). Thus, T cells specific for a
tumor antigen will not be activated by an initial encounter with
tumor cells or may even be rendered anergic because, with the
exception of a few lymphomas, tumors do not express costimu-
latory B7 molecules (Townsend and Allison, 1993). Thus, tumors
are essentially invisible to T cells until the T cells are activated as
a result of cross-priming by dendritic cells that present tumor
antigens acquired from dying tumor cells. Simultaneous recogni-
tion of antigen/MHC complexes and costimulatory ligands by
T cells initiates a complex set of genetic programs that result in
cytokine production, cell-cycle progression, and production of
anti-apoptotic factors that result in proliferation and functional
differentiation of T cells. Consistent with the importance of
both antigen receptor and costimulatory signals in initiating
anti-tumor responses, many therapeutic vaccines now incorpo-
rate both antigen and dendritic cells or agents that enhance cos-
timulatory signaling.
By the mid-90s, it became clear that T cell priming elicits not
only programs leading to induction of T cell responses but also
a parallel program that will eventually stop the response. The crit-
ical inhibitory program is mediated by CTLA-4, a homolog of
CD28 that also binds B7-1 and B7-2, although with much greater
avidity than that CD28. Expression of the ctla-4 gene is initiated
upon T cell activation, and it traffics to and accumulates in the
immunological synapse, eventually attenuating or preventing
CD28 costimulation by competition for B7 binding and negative
signaling (Walunas et al., 1994; Krummel and Allison, 1995). The
fact that ctla-4 knockout mice suffer from a rapid and lethal
lymphadenopathy (Waterhouse et al., 1995; Tivol et al., 1995;
Chambers et al., 1997) speaks for a negative role for CTLA-4 in
limiting T cell responses to prevent damage to normal tissues.
Thus, activation of T cells as a result of antigen receptor
signaling and CD28 costimulation is followed not only by induc-
tion of genetic programs leading to proliferation and functional
differentiation but also by induction of an inhibitory program
mediated by CTLA-4, which will ultimately stop proliferation.
Extrapolating this paradigm to anti-tumor T cell responses, if
eradication of the tumor has not been completed by the time
that the inhibitory signal of CTLA-4 is triggered, the T cells will
be turned off and will be unable to complete the task. Impor-
tantly, this also suggests that, after this program is initiated,
vaccines used to stimulate antigen receptor signaling may
actually serve to strengthen the ‘‘off’’ signal as a result of addi-
tional induction of ctla-4 expression by antigen receptor
signaling. In any event, this suggests the importance of shifting
strategies for cancer immunotherapy from activating T cells to
unleashing them.
Inactivating the Brakes to Increase Anti-tumor Immunity
Consistent with the observations that CD28 and CTLA-4 had
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was found that, although blocking antibodies to CD28 impaired
anti-tumor responses in mice, blocking antibodies to CTLA-4
enhanced anti-tumor responses in mouse tumor models (Leach
et al., 1996). In fact, the treatment of mice with anti-CTLA-4
antibodies as monotherapy results in complete tumor rejection
and long-lived immunity. Later on, mechanistic studies revealed
that anti-tumor activity was associated with increased ratio of
both CD4 and CD8 effector cells to FoxP3+ regulatory T cells
(Quezada et al., 2006). The success of CTLA-4 blockade in these
initial studies raised two compelling points. First, because the
target molecule was on the T cell and not the tumor cell, it was
feasible to imagine that the same strategy would work on
many different histologic tumors, as well as on tumors caused
by different genetic lesions. Second, taking into consideration
that CTLA-4 inhibited CD28-mediated costimulation by a cell-
intrinsicmechanism (Peggs et al., 2009), its blockade could allow
for enhanced T cell costimulation, which in turn would increase
the efficacy of tumor vaccines, as well as agents that kill tumor
cells under conditions that promote inflammatory responses.
These possibilities were further supported by the results of a
series of studies in different mouse models, including the
demonstration that blockade of CTLA-4 was not limited to any
particular tumor type but was rather broadly effective. CTLA-4
also was able to synergize with a vaccine consisting of tumor
cells engineered to express the cytokine GM-CSF to eradicate
tumors (Hurwitz et al., 1998; van Elsas et al., 1999). Finally,
CTLA-4 could be combined with local delivery of irradiation,
cryoablation, or an oncolytic virus to induce systemic tumor im-
munity and eradication of distant metastases (Zamarin et al.,
2014; Waitz et al., 2012; Tang et al., 2014). These preclinical
studies supported the development of clinical anti-CTLA-4
therapy.
Immune Checkpoint Therapy: The Clinical Success
CTLA-4 blockade was translated to the clinic with a fully human
antibody to human CTLA-4 (ipilimumab, Medarex, Bristol-Myers
Squibb). Tumor regression was observed in phase I/II trials in
patients with a variety of tumor types, including melanoma, renal
cell carcinoma, prostate cancer, urothelial carcinoma, and
ovarian cancer (Yang et al., 2007; Hodi et al., 2008; Carthon
et al., 2010; van den Eertwegh et al., 2012). Two phase III clinical
trials with ipilimumab were recently completed in prostate can-
cer, the first in patients with castrate-resistant prostate cancer
who had not received prior chemotherapy treatment and the
second in a more advanced disease setting, in which patients
with castrate-resistant prostate cancer presented disease that
had progressed on chemotherapy treatment. The former trial is
yet to be reported. The latter trial reports the lack of statistical
significance (p value of 0.053) to indicate a survival benefit for
patients who received ipilimumab treatment. However, subset
analyses indicate that patients who have favorable clinical char-
acteristics such as lack of liver metastases do benefit from ipili-
mumab therapy (Kwon et al., 2014). Two phase III clinical trials
with anti-CTLA-4 (ipilimumab) were also conducted in patients
with advanced melanoma and demonstrated improved overall
survival for patients treated with ipilimumab (Hodi et al., 2010;
Robert et al., 2011). Importantly, these trials indicate long-term
durable responses with greater than 20% of treated patients208 Cell 161, April 9, 2015 ª2015 Elsevier Inc.living for more than 4 years, including a recent analysis indicating
survival of 10 years or more for a subset of patients (Schadendorf
et al., 2015). The FDA approved ipilimumab as treatment for
patients with melanoma in 2011.
The clinical success of anti-CTLA-4 opened a new field termed
‘‘immune checkpoint therapy’’ as additional T cell intrinsic path-
ways were identified and targeted for clinical development
(Sharma et al., 2011; Pardoll, 2012). Another T-cell-intrinsic
inhibitory pathway identified after CTLA-4 was that mediated
by PD-1 (programmed death 1) and its ligand PD-L1. PD-1 was
initially cloned in 1992 in a study of molecules involved in nega-
tive selection of T cells by programed cell death in the thymus
(Ishida et al., 1992). Its function as an immune checkpoint was
not established until 2000 upon identification of its ligands
(Freeman et al., 2000). PD-L1 was then shown to protect tumor
cells by inducing T cell apoptosis (Dong et al., 2002). Later,
preclinical studies in animal models evaluated anti-PD-1 and
anti-PD-L1 antibodies as immune checkpoint therapies to treat
tumors (Keir et al., 2008).
Much like CTLA-4, PD-1 is expressed only in activated T cells.
However, unlike CTLA-4, PD-1 inhibits T cell responses by inter-
fering with T cell receptor signaling as opposed to outcompeting
CD28 for binding to B7. PD-1 also has two ligands, PD-L1 and
PD-L2. PD-L2 is predominantly expressed on APCs, whereas
PD-L1 can be expressed on many cell types, including cells
comprising the immune system, epithelial cells, and endothelial
cells. Antibodies targeting PD-L1 have shown clinical responses
in multiple tumor types, including melanoma, renal cell carci-
noma, non-small-cell lung cancer (Brahmer et al., 2012), and
bladder cancer (Powles et al., 2014). Similarly, phase I clinical
trials with a monoclonal antibody against PD-1 demonstrated
clinical responses in multiple tumor types, including melanoma,
renal cell carcinoma, non-small-cell carcinoma (Topalian et al.,
2012), Hodgkin’s lymphoma (Ansell et al., 2015), and head and
neck cancers (Seiwert et al., 2014, J. Clin. Oncol., abstract).
Recently, a large phase I clinical trial with an anti-PD-1 antibody
known as MK-3475 showed response rates of 37%–38% in
patients with advanced melanoma, including patients who had
progressive disease after prior ipilimumab treatment (Hamid
et al., 2013), triggering the approval of MK-3475 (pembroluzi-
mab, Merck) by the FDA in September 2014. A phase III clinical
trial that treated patients with metastatic melanoma with a
different anti-PD-1 antibody (nivolumab, Bristol-Myers Squibb,
BMS) also demonstrated improved responses and overall sur-
vival benefit as compared to chemotherapy treatment (Robert
et al., 2015b). Nivolumab was FDA approved for patients with
metastatic melanoma in December 2014. In addition, nivolumab
was FDA approved in March 2015 for patients with previously
treated advanced or metastatic non-small-cell lung cancer
based on a phase III clinical trial, which reported an improvement
in overall survival for patients treated with nivolumab as
compared to patients treated with docetaxel chemotherapy.
Because CTLA-4 and PD-1 regulate different inhibitory path-
ways on T cells, combination therapy with antibodies targeting
both molecules was tested and found to improve anti-tumor re-
sponses in a pre-clinical murine model (Curran et al., 2010). A
recently reported phase I clinical trial with anti-CTLA-4 in combi-
nation with anti-PD-1 also demonstrated tumor regression
in 50% of treated patients with advanced melanoma, in most
cases with tumor regression of 80% or higher (Wolchok et al.,
2013). There are ongoing clinical trials with anti-CTLA-4
(ipilimumab, BMS or tremelimumab, MedImmune/Astrazeneca)
plus anti-PD-1 or anti-PD-L1 in other tumor types, with prelimi-
nary data indicating promising results (Hammers et al., 2014,
J. Clin. Oncol., abstract; Callahan et al., 2014, J. Clin. Oncol.,
abstract) that highlight this combination as an effective immuno-
therapy strategy for cancer patients.
As with other cancer therapies, immune checkpoint therapies
may lead to side effects and toxicities (see Postow et al., 2015;
Gao et al., 2015 for recent reviews). Briefly, these side effects
consist of immune-related adverse events that are defined by in-
flammatory conditions, including dermatitis, colitis, hepatitis,
pancreatitis, pneumonitis, and hypophysitis. These side effects
can be managed and usually involve administration of immuno-
suppressive agents such as corticosteroids, which do not
appear to interfere with clinical benefit that is derived from
the immune checkpoint agents. The profile of side effects that
occur with both anti-CTLA-4 and anti-PD-1/PD-L1 antibodies
is similar; however, the side effects appear to occur more
frequently in the setting of anti-CTLA-4 therapy as compared
to anti-PD-1 and anti-PD-L1 therapies. The continued success
of immune checkpoint therapies in the clinic will require educa-
tion of the oncology community regarding recognition and treat-
ment of the side effects elicited by these agents.
Novel Immunologic Targets for Cancer Immunotherapy
Although blockade of the CTLA-4 and PD-1/PD-L1 pathways is
furthest along in clinical development, it only represents the tip
of the iceberg in the realm of potential targets that can serve to
improve anti-tumor responses. Ongoing studies on regulation
of immune responses have led to the identification of multiple
other immunologic pathways that may be targeted for the devel-
opment of therapies, either as monotherapy or in combination
strategies, for the successful treatment of cancer patients. These
include immune checkpoints or inhibitory pathways, as well as
co-stimulatory molecules, which act to enhance immune re-
sponses. A partial list of new immune checkpoints that are being
evaluated in pre-clinical tumor models and/or in the clinic with
cancer patients includes LAG-3 (Triebel et al., 1990), TIM-3
(Sakuishi et al., 2010), and VISTA (Wang et al., 2011), whereas
co-stimulatory molecules include ICOS (Fan et al., 2014), OX40
(Curti et al., 2013), and 4-1BB (Melero et al., 1997).
Of these emerging immune checkpoints, LAG-3 is the furthest
along in clinical development with a fusion protein (IMP321,
Immuntep) and an antibody (BMS-986016, BMS) in clinical trials.
The fusion protein was tested as monotherapy in patients with
renal cell carcinoma, which was well tolerated and led to stabili-
zation of disease in some patients (Brignone et al., 2009).
IMP321 was also tested in combination with paclitaxel chemo-
therapy in patients with metastatic breast cancer, which led
to an objective response rate of 50% (Brignone et al., 2010).
Based on these promising results, a phase III clinical trial is
expected to begin accrual in 2015. Other clinical trials are
ongoing with an antibody against LAG-3 (BMS-986016), which
is also being tested in combination with anti-PD-1 (nivolumab)
(NCT01968109, http://www.clinicaltrials.gov). TIM-3 is anotherimmune checkpoint for which agents are being developed for
clinical testing. Pre-clinical studies indicate that TIM-3 is co-
expressed with PD-1 on tumor-infiltrating lymphocytes, and
combination therapy targeting these two pathways improves
anti-tumor immune responses (Sakuishi et al., 2010). Finally, an
antibody targeting VISTA was recently shown to improve anti-
tumor immune responses in mice (Le Mercier et al., 2014), with
clinical development soon to follow. Again, these agents repre-
sent only a partial list of the immune checkpoint agents that
are currently under development for clinical testing, with expec-
tations that they will be tested in combination strategies based
on in-depth analyses of human tumors to provide an understand-
ing of co-expression of these, and other immunologic targets, to
guide rational combinations.
Regarding the co-stimulatory molecules, OX40 and 41BB,
which are members of the TNF-receptor superfamily, are
furthest along in clinical development. A murine anti-OX40 anti-
body, given as a single dose, was tested in a phase I clinical trial
and found to have an acceptable safety profile, as well as evi-
dence of anti-tumor responses in a subset of patients (Curti
et al., 2013). Humanized antibodies against OX40 are expected
to enter clinical trial in 2015. Anti-41BB (BMS-663513) is a fully
humanized monoclonal antibody that has been tested in a phase
I/II study in patients with melanoma, renal cell carcinoma, and
ovarian cancer, with promising clinical responses, as well as
toxicities, especially at higher doses, which led to re-evaluation
of the dose and schedule of treatment (Sznol et al., 2008,
J. Clin. Oncol., abstract). Currently, there are five clinical trials
with anti-41BB (urelumab, BMS-663513) that are recruiting pa-
tients with various tumor types (http://www.clinicaltrials.gov),
including combination with anti-PD-1 (nivolumab), with data ex-
pected to be presented from these trials during the next 1 to 2
years. The third co-stimulatory molecule is inducible co-stimu-
lator (ICOS), a member of the CD28/B7 family whose expression
increases on T cells upon T cell activation. ICOS+ effector T cells
(Teff), as opposed to ICOS+ regulatory T cells (Treg), increase
after patients receive treatment with anti-CTLA-4 (Liakou et al.,
2008), correlating with clinical benefit in a small retrospective
study (Carthon et al., 2010). ICOS thus may serves as a pharma-
codynamic biomarker to indicate that anti-CTLA-4 has ‘‘hit its
target’’ enhancing T cell activation (Ng Tang et al., 2013). Also,
the association of agonistic targeting of ICOS and blockade of
CTLA-4 can lead to improved anti-tumor immune responses
and tumor rejection in mice (Fan et al., 2014). Anti-ICOS anti-
bodies are expected to enter into clinical trials in 2015. It is likely
that combination therapy to simultaneously engage co-stimula-
tory pathways and limit inhibitory pathways will be a successful
path forward to provide clinical benefit. Importantly, based on
the profile of toxicities observed to date, it will be critical
to closely monitor these combination strategies for potential
adjustments of dosage and management of toxicities that may
arise.
Reconciliation: Curative Therapeutic Combinations
The last few decades have witnessed the emergence of two
effective but fundamentally different strategies for cancer ther-
apy, each with its own strengths and weaknesses. Genomic-
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Figure 1. Combination TherapyMay Improve Anti-tumor Responses
Depiction of tumor cells dying as a result of genomically targeted therapies
with release of tumor antigens; tumor antigens are taken up by APCs and are
presented in the context of B7 costimulatory molecules to T cells; T cells
recognize antigens on APCs to become activated; activated T cells also up-
regulate inhibitory checkpoints such as CTLA-4 and PD-1; immune checkpoint
therapy prevents attenuation of T cell responses, thereby allowing T cells to kill
tumor cells; and T cells may differentiate into memory T cells that can re-
activate in the presence of recurrent tumor.
210 Cell 161, April 9, 2015 ª2015 Elsevier Inc.the development of drugs that result in remarkable responses in
the majority of patients whose tumors have the targeted lesion,
but the responses are relatively short-lived. As was the case
with chemotherapies, it is not unreasonable that combinations
of genomically targeted agents will be more powerful against
cancer than single agents. It is possible that the use of multiple
agents may enhance their effectiveness in terms of increasing
overall survival. However, the myriad of mechanisms of acquired
resistance and the complexity of the target landscape due to
inherent genomic instability may prove extremely difficult to
overcome through the sole use of genomically targeted strate-
gies, attaining to achieve cure. In contrast, immune checkpoint
therapy is inherently multivalent because targeting a single
checkpoint can potentially release T cells with specificity for
peptides derived from many different antigens present in a
tumor, including differentiation, cancer testis, and even neoanti-
gens generated by mutational events inherent in the genomic
instability that drives cancer (Snyder et al., 2014; Linnemann
et al., 2015). As a result of the generation of improved anti-tumor
T cell responses, immune checkpoint therapy results in durable
responses but only in a fraction of patients. As discussed in the
previous sections, it is certainly possible to target multiple
immune checkpoints with different mechanisms for improved
anti-tumor responses in greater numbers of patients. Will pa-
tients benefit from combination of these two strategies?
Efforts to combine molecularly targeted agents and immuno-
therapy have already begun. A phase I clinical trial with agents
that inhibit receptor tyrosine kinases, sunitinib, or pazopbnib,
in combination with anti-PD-1, was recently reported and
showed promising overall response rates of 40%–50% in pa-
tients with metastatic renal cell carcinoma (RCC) (Amin et al.,
2014, J. Clin. Oncol., abstract). These types of combinations
will require further follow-up to evaluate for survival and durability
of responses. An area that has not yet received enough attention
is the immunological impact of genetically targeted agents.
Vemurafenib, an FDA-approved BRAF inhibitor used for the
treatment of melanoma, has been shown to increase expression
of tumor antigens and MHC molecules (Frederick et al., 2013),
increasing the sensitivity of the tumor cells to immune attack.
Vemurafenib also has potent effects on T cells, enhancing the
effects of antigen-mediated activation, perhaps as a result of
enhanced activation of the MAP kinase pathway after T cell
antigen receptor signaling (Atefi et al., 2014). These data sug-
gest that certain agents may be well suited for combination
with immunotherapy. However, a clinical trial testing a BRAF in-
hibitor (vemurafenib) in combination with anti-CTLA-4 (ipilimu-
mab) was terminated due to hepatotoxicity (Ribas et al., 2013).
A second clinical trial with a BRAF inhibitor (dabrafenib) in com-
bination with anti-CTLA-4 (ipilimumab) is currently ongoing, and
Figure 2. Improved Overall Survival as a Result of Combination
Therapy
Depiction of Kaplan-Meier survival curve with genomically targeted agents
(blue line) as compared to standard therapies (purple line), indicating an
improvement in median overall survival but lack of durable responses;
improved median overall survival and durable responses in a fraction of
patients treated with immune checkpoint therapy (green line); possibility for
improved median overall survival with durable responses for the majority of
patients in the setting of combination treatment with genomically targeted
agents and immune checkpoint therapy (red line).preliminary data indicate that this combination appears to be
well tolerated (Puzanov et al., 2014, J. Clin. Oncol., abstract),
which highlights the need to consider differences in drugs,
dose, and/or schedule when evaluating agents for combination
strategies. Understanding how different genetically targeted
agents affect the responsiveness to immunotherapy may help
guide choices of combinations of drugs.
From a mechanistic perspective, it is possible that combina-
tion strategies with immune checkpoint therapies and genomi-
cally targeted agents will result in induction of immune memory,
leading to more durable control of tumor growth than what is
achievable with either modality alone. Genomically targeted
therapies with high objective response rates actually could serve
as ‘‘cancer vaccines,’’ inducing the killing of tumor cells and re-
sulting in the release of tumor antigens and neoantigens, which
can then be presented by APCs to tumor-specific T cells
(Figure 1). These T cells would become activated but also upre-
gulate inhibitory checkpoints such as CTLA-4 and PD-1, which
can be blocked with antibodies to permit enhanced anti-tumor
T cell responses, including memory T cell responses, to enable
long-term control of disease and possible cure. In addition, the
use of targeted agents to directly kill tumor cells, with release
of tumor antigens, may focus the activated immune response
generated by immunotherapy agents on tumor antigens rather
than self-antigens expressed on normal tissues, resulting in
fewer adverse events. Furthermore, identification of neoantigens
may result in the development of personalized vaccines
composed of these neoantigens for novel vaccine strategies
plus immune checkpoint agents (Gubin et al., 2014; Tran et al.,
2014; Linnemann et al., 2015).
Although it is clear that clinical responses can be elicited with
immune checkpoint therapies or genomically targeted agents, itappears that genomically targeted agents alone tend to improve
median survival without providing long-term durable responses
(Figure 2, blue line). Targeting immune checkpoints improves
median survival but remarkably also provides long-term durable
responses, raising the tail of the survival curve (Figure 2, green
line). When combined, these therapies are likely to have an addi-
tive or even synergistic therapeutic effect that not only would
potentially further improve median survival but would also raise
the tail of the survival curve, increasing the number of patients
that appreciate long-term clinical benefit (Figure 2, red line).
A Future of Curative Cancer Therapies
Federal funding for research has been overwhelmingly directed
toward genomically targeted therapies as compared to immune
checkpoint therapies. The fundamental research that led to the
identification of CTLA-4 as an immune checkpoint, as well as
the pre-clinical studies showing the potential of its blockade in
cancer therapy, were funded by the National Cancer Institute,
but since then, there have been no major initiatives to accelerate
progress in this area. Given the durability of the responses that
have been obtained with immune checkpoint therapies, it seems
reasonable also to allocate enough funds and resources to
research focused on immune checkpoint therapies and combi-
nation therapy of genomically targeted agents and immuno-
therapy with promising curative potential. Efforts to determine
the impact of genomically targeted therapies on the immune sys-
tem should also be prioritized, as they will help to identify which
agents can enhance anti-tumor T cell responses and guide the
choice of combinations from the two classes of agents. At this
stage, it does not seem a stretch to say that increasing funding
to combination therapies will be key to development of new
safe treatments that may prove to be curative for many patients
with many types of cancer.
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